Research programme: autoimmune disorder therapeutics - Asahi Kasei Pharma/Vernalis
Latest Information Update: 03 Oct 2013
At a glance
- Originator Asahi Kasei Pharma Corp; Vernalis
- Developer Asahi Kasei; Vernalis
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders; Rheumatoid arthritis
Most Recent Events
- 01 Oct 2013 Early research in Autoimmune disorders and Rheumatoid arthritis in United Kingdom and Japan (unspecified route)